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Abstract
All the standard in vitro lipofection has been routinely performed in serum-free medium as the transfection activity of
liposome/DNA complexes is sensitive to the presence of serum. In this study, we have demonstrated that lipid-rich serum
lipoprotein included in the transfection medium strongly inhibited the transfection activity of DC-chol liposome/DNA
complexes in five different cell types (CHO, 293, A2780CP, A431 and SKBR3). The levels of inhibition by serum lipoprotein
were rather greater than those by serum and varied with cell types. However, this inhibition was completely abolished by
delipidation of serum. Thus, delipidated serum can be included in the transfection medium. The complexes formed in the
presence of serum (j=318.2 þ 1.07 mV), delipidated serum (j=319.6 þ 0.54 mV), IgG (j=321.6 þ 1.92 mV) or serum
lipoprotein (j=310.5 þ 2.33 mV) were as much negatively charged as those in serum-free medium (j=321.3 þ 1.60 mV).
The results suggest that the inhibition of liposome-mediated transfection by serum was not associated with charges of serum
proteins but with lipids or lipid-associated proteins present in serum. ß 2001 Published by Elsevier Science B.V.
Keywords: Lipofection; DNA/liposome complex; Surface charge; Lipoprotein; Delipidated serum
Delivery of genetic material into cells is mediated
by a variety of methods, DEAE-dextran, calcium
phosphate, electroporation, cationic liposomes, virus,
biolistic particles, microinjection, etc. Among them,
cationic liposomes have been demonstrated as an ef-
¢cient and safe transfection reagent in experimental
animals and human gene therapy clinical trials [1,2].
However, one drawback of liposome-mediated trans-
fection (lipofection) is that the presence of serum in
medium during transfection dramatically lowers
transfection e⁄ciency [3^7]. In this reason, the opti-
mal condition for in vitro transfection with a lipo-
some reagent omits serum in the lipofection medium.
This drawback also hampers the application of cat-
ionic liposomes for in vivo delivery of genes. The
liposomes currently in use typically contain a mixture
of cationic and neutral lipids. Transfection complex
formation is based on the interaction of the posi-
tively charged liposomes with the negatively charged
phosphate groups of the nucleic acid. Thus, ¢nding
factor(s) in serum inhibiting the transfection e⁄-
ciency of cationic liposome/DNA complexes (lipo-
plexes) can lead a rational design of transfection
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becco’s modi¢cation of Eagle’s medium; HDL, high density lipo-
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complex formulation for in vitro transfection and in
vivo gene delivery.
To ¢nd the inhibitory factor(s) present in serum,
we examined the e¡ect of serum proteins on the
transfection e⁄ciency in ¢ve di¡erent cell types.
Those cell lines were CHO Chinese hamster ovary
(a gift from Dr. M.M. Gottesman, National Cancer
Institute, Bethesda, MD, USA), 293 human embry-
onal kidney (ATCC), A2780CP cisplatin-resistant
variant of human ovarian carcinoma (a gift from
Dr. K.J. Scanlon, City of Hope National Medical
Center, Duarte, CA, USA), A431 human epidermoid
carcinoma (ATCC), and SKBR3 human breast car-
cinoma (ATCC). Cells were grown in RPMI 1640
or Dulbecco’s modi¢cation of Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) containing penicillin (100
U/ml)/streptomycin (100 Wg/ml), and glutamine (2
mM). Albumin, the most abundant protein in serum,
was tested and con¢rmed to enhance in vitro lipofec-
tion e⁄ciency as reported [8]. The other two major
serum proteins are immunoglobulins and lipopro-
teins. Table 1 shows the concentrations of immuno-
globulin G (IgG) (Sigma I5506) and lipoprotein (Sig-
ma L9906) equivalent to 2.5, 5.0 and 10% of serum,
which were used for transfecting ¢ve cell lines shown
in Fig. 1. Serum lipoprotein used was commercially
available lipoprotein concentrate that contained a
very high amount of lipid (9.8 mg/ml of cholesterol)
and relatively low amount of protein (14.5 mg/ml)
(no other information available from Sigma). Nor-
mal FBS (Gibco/BRL) used contained 1.9^2.3 mg/ml
of total lipids (32^40 mg/dl of cholesterol, 11^13 mg/
dl of HDL, 16^21 mg/dl of LDL, 50^65 mg of phos-
pholipid and 82 mg/dl of triglycerides) and 35 mg/ml
of total protein. Thus, lipid content was 4.3^5.2-fold
higher but protein content was 2.4-fold less in serum
lipoprotein concentrate than in serum.
Inclusion of IgG in the transfection medium did
not signi¢cantly a¡ect the transfection activity in all
¢ve cell lines even at 30 Wg/ml, while inclusion of
serum lipoprotein did in a dose-dependent manner
with the degree of inhibition varying with cell type
(Fig. 1). In vitro transfection was performed by mix-
ing 1 Wg of pUCCMVCAT DNA with 10 nmol of
3L[N-(NP,NP-dimethylaminoethane)carbamoyl]choles-
terol (DC-chol) in an appropriate medium and add-
ing to the cells at 70% con£uency as described [9].
Chloramphenicol acetyltransferase (CAT) gene ex-
pression in the transfected cells was determined as
described [10]. CAT is the bacterial CAT, a reporter
gene, that was used to measure its expression [11].
pUCCMVCAT (5.1 kb) is a pUC18-based plasmid
containing the full-length CAT cDNA and was pu-
ri¢ed by Qiagen Plasmid Giga kit (Valencia, CA,
USA) according to the manufacturer’s instructions
and dissolved in TE bu¡er (10 mM Tris and 1 mM
EDTA, pH 8.0). DC-chol liposomes were composed
of DC-chol and dioleoyl phosphatidylethanolamine
(3:2 mol ratio) which were combined in chloroform,
dried thoroughly, and hydrated with deionized water
(pH 7.50 þ 0.25) as described [12]. The transfection
activity in CHO and A431 cells was completely in-
hibited by the presence of 50 and 25 Wg/ml of serum
lipoprotein, respectively, in the transfection medium
(Fig. 1A,D). This inhibition was somewhat less pro-
nounced in 293 (maximum 61%), A2780CP (maxi-
mum 65%) and SKBR3 (maximum 53%) cells trans-
Table 1
Concentrations of serum protein used in the lipofection medium
for transfecting ¢ve cell lines shown in Fig. 1
Serum protein Concentration (%)
0 2.5 5.0 10 100a
IgG (Wg/ml) 0 7.5 15 30 50^300
Lipoprotein (Wg/ml) 0 12.5 25 50 290^500
aNormal untreated fetal bovine serum.
C
Fig. 1. CAT gene expression in ¢ve cell lines transfected with liposome/DNA complexes in the presence of serum, serum protein or
delipidated serum. (A) Chinese hamster ovary CHO, (B) human embryonal kidney 293, (C) cisplatin-resistant variant of human ovar-
ian carcinoma A2780CP, (D) human epidermoid carcinoma A431 and (E) human breast carcinoma SKBR3. Cells were grown in com-
plete medium. The cells at 70% con£uency were seeded into 24 well plates overnight before transfection. One Wg of pUCCMVCAT
DNA (1 Wg/Wl) and 10 nmol of DC-chol (2 nmol/Wl) were mixed in medium (RPMI 1640 or DMEM) containing three di¡erent con-
centrations of serum, IgG, lipoprotein, or delipidated serum, added to the washed cells and incubated for 5 h. The transfected cells
were further incubated in complete medium for 48 h followed by lysis and CAT activity assay as described [9]. Each data point is
mean þ S.D. of three replicate cultures. FBS, fetal bovine serum; IgG, immunoglobulin G.
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fected in the presence of 50 Wg/ml of serum lipopro-
tein (Fig. 1B,C,E). Unlike lipoprotein, there was no
complete inhibition of lipofection in any ¢ve cell
lines in the presence of serum (Fig. 1). In fact, the
strong inhibitory e¡ects of serum lipoprotein on lipo-
fection were even more dramatic than those of serum
in CHO and A431 cell lines (Fig. 1A,D). The degree
of inhibition by serum lipoprotein in 293, A2780CP
and SKBR3 cells was similar to that by serum as
the concentration increased. We also observed that
expression of a target gene inducible nitric oxide
synthase, routinely used for the treatment of drug-
resistant ovarian and breast tumor in our laboratory,
in A2780CP cells was also inhibited by the presence
of serum or serum lipoprotein in the transfection
medium to a similar extent to CAT expression
(data not shown). The results suggest that lipopro-
tein is a major inhibitory factor present in serum on
lipofection.
To test if the inhibition was associated with lipids,
we used the medium containing delipidated serum
during transfection. Delipidated FBS used contained
6 mg/dl of cholesterol, 3 mg/dl of HDL, 1 mg/dl of
LDL, 12 mg/dl of phospholipid (no information on
triglycerides content) and 3.5 g/dl of total protein
(Cocalico Biologicals). Thus, delipidated serum had
85^95% less lipid than normal serum. Surprisingly
enough, inclusion of delipidated serum in the trans-
fection medium not only abolished the strong inhib-
itory e¡ect of lipoprotein on the lipofection activity
in four cell lines, CHO, 293, A431 and SKBR3, but
also signi¢cantly enhanced transfection of A2780CP
cells (maximum 1.6-fold) (Fig. 1). These results sup-
port that the inhibitory e¡ect of lipoprotein on lipo-
fection is due to lipids associated with it. Thus, de-
lipidated serum can be included in the transfection
medium and cells can be incubated longer than 5 h, a
time used in serum-free medium, to achieve higher
transfection e⁄ciency. It is evident that in vivo gene
delivery is much less e⁄cient than in vitro transfec-
tion as normal human plasma contains a large
amount of lipids (a total lipid content of 3.6^6.8 g/
l). A better transfection complex formulation to
block the inhibitory e¡ect of lipids present in serum,
blood or tissue will greatly enhance in vitro trans-
fection as well as in vivo gene delivery.
To test if the inhibition of lipofection by serum
was also associated with large amounts of negatively
charged serum proteins as previously reported [5], we
measured zeta potential (surface charge density) of
liposome/DNA complexes formed in the absence
and presence of serum, serum protein or delipidated
serum (Fig. 2). The parameters used to measure j
were as follows [13]: j model = Smoluchowski, ¢eld
frequency = 2.00 Hz, voltage = 3.00 V, temperature =
25‡C, viscosity = 0.0890 cP, re£ex index = 1.330,
angle = 90‡, and wavelength = 676 nm. We used
DMEM (pH = 7.27 þ 0.02, the ionic strength calcu-
lated from the formulation = 0.17) which was ¢ltered
through a 0.2 Wm membrane. Charge-associated
transfection e⁄ciency can be predicted by zeta po-
tential [13]. Cationic liposomes were slightly posi-
tively charged in serum-free medium (j= 4.16 þ 1.75
mV) but negatively charged in the presence of serum
(j=37.50 þ 1.70 mV). This indicates that liposomes
did interact with negatively charged serum proteins.
However, as we previously demonstrated [9], when
DNA was present, the complexes were highly nega-
tively charged not only in serum-free medium
(j=321.3 þ 1.60 mV) but also in the presence of
serum (j=318.2 þ 1.07 mV) or delipidated serum
Fig. 2. Zeta potential of liposome/DNA complexes formed in
the presence of serum, serum protein or delipidated serum. Ap-
propriate concentration of serum or serum protein in DMEM
was mixed with 1 Wg of pUCCMVCAT DNA and then added
to 10 nmol of DC-chol liposomes (the total volume of 250 Wl).
These mixtures were subjected to the measurement of zeta po-
tential. All measurements were made in triplicate and expressed
as the mean þ S.D. FBS, fetal bovine serum; IgG, immunoglob-
ulin G.
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(j=319.6 þ 0.54 mV). Furthermore, the complexes
were still negatively charged in the presence of IgG
(j=321.1 þ 1.92 mV) or lipoprotein (j=310.5 þ
2.33 mV), although those with lipoprotein were
slightly less negative (Fig. 2). Despite a dramatic dif-
ference in the lipofection e⁄ciency of the complexes
formed between normal and delipidated serum in the
transfection medium, zeta potential of the complexes
remained little changed. These results indicate that
the inhibition e¡ect of serum was not due to negative
charges introduced from serum proteins. This ¢nding
supports, in part, our previous report that negatively
charged complexes were not only much more e⁄cient
to deliver gene to solid tumors than positively
charged ones but also as e⁄cient as positively
charged ones to deliver gene to ascitic-like tumors
[14]. Furthermore, we did not observe signi¢cant
changes in the size of the complexes in the presence
of serum or serum proteins (the hydrodynamic diam-
eter = 300^370 nm) (data not shown). Therefore, less
e⁄cient in vivo gene delivery may not be associated
with neither charges or size of the complexes. It is
lipids or lipid-associated proteins present in serum,
blood or tissue that liposome/DNA complexes inter-
act with, reducing in vitro and in vivo gene delivery.
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